Nanotechnology Now







Heifer International

Wikipedia Affiliate Button


DHgate

Home > News > American Pharmaceutical Partners Reports Tolerability of High Dose

June 8th, 2004

American Pharmaceutical Partners Reports Tolerability of High Dose

Abstract:
Abraxis Oncology, a division of American Pharmaceutical Partners, Inc. today reported results of a Phase I dose-escalation study of ABRAXANETM (albumin nanoparticle paclitaxel) that indicated this investigational drug is well-tolerated at high doses in a weekly dosing schedule for non-hematologic malignancies such as lung, ovarian and metastatic breast cancer and patients who have had prior chemotherapies.

Source:
APP

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Nanomedicine

New nanodevice defeats drug resistance: Tiny particles embedded in gel can turn off drug-resistance genes, then release cancer drugs March 2nd, 2015

New Hopes for Treatment of Intestine Cancer by Edible Nanodrug March 2nd, 2015

Graphene Shows Promise In Eradication Of Stem Cancer Cells March 1st, 2015

Novel Method to Determine Optical Purity of Drug Components March 1st, 2015

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More










ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2015 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE